Literature DB >> 18410949

Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells.

Lynda A Morrison1.   

Abstract

Replication-defective herpes simplex virus 2 (HSV-2), used as an immunization strategy, protects against HSV-2 challenge in animal models. The roles of replication-defective virus-induced T cell subsets in control of HSV-2 infection have not been established. Mice lacking B cells (microMT) were immunized, depleted of CD4 or CD8 T cells, and then challenged intravaginally with HSV-2 to elucidate T cell subset contributions in the absence of virus-specific antibody. Immunized, CD4-depleted microMT mice developed severe infection of the genital tract and nervous system. In contrast, depletion of CD8 T cells from microMT mice did not attenuate protection. Immunized wild-type mice depleted of CD4 T cells also developed more severe HSV-2 infection than mice from which CD8 T cells were depleted. Thus, immunization with replication-defective virus induces T cell responses that effectively control HSV-2 infection in the absence of HSV-immune antibody, and CD4 T cells play the predominant role in this protective effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410949      PMCID: PMC2431983          DOI: 10.1016/j.virol.2008.03.010

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

1.  Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.

Authors:  L A Morrison; D M Knipe
Journal:  Virology       Date:  1996-06-15       Impact factor: 3.616

2.  Anti-glycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes.

Authors:  A M Eis-Hübinger; D S Schmidt; K E Schneweis
Journal:  J Gen Virol       Date:  1993-03       Impact factor: 3.891

3.  Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract.

Authors:  G N Milligan; D I Bernstein
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

4.  Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization.

Authors:  W S Gallichan; K L Rosenthal
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

5.  Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig.

Authors:  D J Topham; R A Tripp; A M Hamilton-Easton; S R Sarawar; P C Doherty
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

6.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

7.  A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.

Authors:  M B Parr; L Kepple; M R McDermott; M D Drew; J J Bozzola; E L Parr
Journal:  Lab Invest       Date:  1994-03       Impact factor: 5.662

8.  Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.

Authors:  G N Milligan; D I Bernstein
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

9.  Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract.

Authors:  G N Milligan; D I Bernstein
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

10.  CD8 T cell memory in B cell-deficient mice.

Authors:  M S Asano; R Ahmed
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  13 in total

1.  Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Authors:  Timothy E Dudek; Ernesto Torres-Lopez; Clyde Crumpacker; David M Knipe
Journal:  J Infect Dis       Date:  2011-04-14       Impact factor: 5.226

Review 2.  Generating protective immunity against genital herpes.

Authors:  Haina Shin; Akiko Iwasaki
Journal:  Trends Immunol       Date:  2013-09-03       Impact factor: 16.687

Review 3.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 4.  Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

Authors:  Gargi Dasgupta; Lbachir BenMohamed
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

Review 5.  The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Authors:  Tiffany Kuo; Christine Wang; Tina Badakhshan; Sravya Chilukuri; Lbachir BenMohamed
Journal:  Vaccine       Date:  2014-10-16       Impact factor: 3.641

6.  Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice.

Authors:  Sri P Vagvala; Lydia G Thebeau; Saydra R Wilson; Lynda A Morrison
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

7.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

8.  HSV-1 strain McKrae is more neuroinvasive than HSV-1 KOS after corneal or vaginal inoculation in mice.

Authors:  Hong Wang; David J Davido; Lynda A Morrison
Journal:  Virus Res       Date:  2013-01-20       Impact factor: 3.303

9.  Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.

Authors:  Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Curr Trends Immunol       Date:  2012

10.  A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Authors:  X Zhang; A A Chentoufi; G Dasgupta; A B Nesburn; M Wu; X Zhu; D Carpenter; S L Wechsler; S You; L BenMohamed
Journal:  Mucosal Immunol       Date:  2008-12-24       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.